Voyager Acquisition Corp. (VACH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.86 |
| Open | 1.89 |
| Day High | 1.95 |
| Day Low | 1.78 |
| 52-Week High | 27.36 |
| 52-Week Low | 1.72 |
| Volume | 15,731 |
| Average Volume | 15,520 |
| Market Cap | 56.61M |
| PE | 8.52 |
| EPS | 0.21 |
| Moving Average 50 Days | 12.31 |
| Moving Average 200 Days | 11.07 |
| Change | -0.07 |
Data not available
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
GlobeNewswire Inc.
Mar 11, 2026 10:00 AM GMT
BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Company's Class A ordinary shares (“Class A shares”)
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
GlobeNewswire Inc.
Jul 17, 2025 12:55 PM GMT
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition compa
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
GlobeNewswire Inc.
May 29, 2025 10:34 PM GMT
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and InvestorsZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging